Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

A. Younes, A. Santoro, M. Shipp, PL. Zinzani, JM. Timmerman, S. Ansell, P. Armand, M. Fanale, V. Ratanatharathorn, J. Kuruvilla, JB. Cohen, G. Collins, KJ. Savage, M. Trneny, K. Kato, B. Farsaci, SM. Parker, S. Rodig, MG. Roemer, AH. Ligon, A. Engert,

. 2016 ; 17 (9) : 1283-94. [pub] 20160720

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023835
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 27451390
DOI 10.1016/s1470-2045(16)30167-x
Knihovny.cz E-zdroje

BACKGROUND: Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of PD-1 ligands and evasion of immune surveillance. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed and refractory classical Hodgkin's lymphoma, with an acceptable safety profile. We aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin. METHODS: In this ongoing, single-arm phase 2 study, adult patients (aged ≥18 years) with recurrent classical Hodgkin's lymphoma who had failed to respond to autologous stem-cell transplantation and had either relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Oncology Group performance status score of 0 or 1, were enrolled from 34 hospitals and academic centres across Europe and North America. Patients were given nivolumab intravenously over 60 min at 3 mg/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study. The primary endpoint was objective response following a prespecified minimum follow-up period of 6 months, assessed by an independent radiological review committee (IRRC). All patients who received at least one dose of nivolumab were included in the primary and safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02181738. FINDINGS: Among 80 treated patients recruited between Aug 26, 2014, and Feb 20, 2015, the median number of previous therapies was four (IQR 4-7). At a median follow-up of 8·9 months (IQR 7·8-9·9), 53 (66·3%, 95% CI 54·8-76·4) of 80 patients achieved an IRRC-assessed objective response. The most common drug-related adverse events (those that occurred in ≥15% of patients) included fatigue (20 [25%] patients), infusion-related reaction (16 [20%]), and rash (13 [16%]). The most common drug-related grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase concentrations (four [5%]). The most common serious adverse event (any grade) was pyrexia (three [4%] patients). Three patients died during the study; none of these deaths were judged to be treatment related. INTERPRETATION: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin. Therefore, nivolumab might be a new treatment option for a patient population with a high unmet need. Ongoing follow-up will help to assess the durability of response. FUNDING: Bristol-Myers Squibb.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023835
003      
CZ-PrNML
005      
20240313113600.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(16)30167-X $2 doi
035    __
$a (PubMed)27451390
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Younes, Anas $u Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org.
245    10
$a Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial / $c A. Younes, A. Santoro, M. Shipp, PL. Zinzani, JM. Timmerman, S. Ansell, P. Armand, M. Fanale, V. Ratanatharathorn, J. Kuruvilla, JB. Cohen, G. Collins, KJ. Savage, M. Trneny, K. Kato, B. Farsaci, SM. Parker, S. Rodig, MG. Roemer, AH. Ligon, A. Engert,
520    9_
$a BACKGROUND: Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of PD-1 ligands and evasion of immune surveillance. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed and refractory classical Hodgkin's lymphoma, with an acceptable safety profile. We aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin. METHODS: In this ongoing, single-arm phase 2 study, adult patients (aged ≥18 years) with recurrent classical Hodgkin's lymphoma who had failed to respond to autologous stem-cell transplantation and had either relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Oncology Group performance status score of 0 or 1, were enrolled from 34 hospitals and academic centres across Europe and North America. Patients were given nivolumab intravenously over 60 min at 3 mg/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study. The primary endpoint was objective response following a prespecified minimum follow-up period of 6 months, assessed by an independent radiological review committee (IRRC). All patients who received at least one dose of nivolumab were included in the primary and safety analyses. This trial is registered with ClinicalTrials.gov, number NCT02181738. FINDINGS: Among 80 treated patients recruited between Aug 26, 2014, and Feb 20, 2015, the median number of previous therapies was four (IQR 4-7). At a median follow-up of 8·9 months (IQR 7·8-9·9), 53 (66·3%, 95% CI 54·8-76·4) of 80 patients achieved an IRRC-assessed objective response. The most common drug-related adverse events (those that occurred in ≥15% of patients) included fatigue (20 [25%] patients), infusion-related reaction (16 [20%]), and rash (13 [16%]). The most common drug-related grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase concentrations (four [5%]). The most common serious adverse event (any grade) was pyrexia (three [4%] patients). Three patients died during the study; none of these deaths were judged to be treatment related. INTERPRETATION: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin. Therefore, nivolumab might be a new treatment option for a patient population with a high unmet need. Ongoing follow-up will help to assess the durability of response. FUNDING: Bristol-Myers Squibb.
650    _2
$a dospělí $7 D000328
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a kohortové studie $7 D015331
650    _2
$a kombinovaná terapie $x škodlivé účinky $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a Hodgkinova nemoc $x farmakoterapie $x patologie $x terapie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a imunokonjugáty $x škodlivé účinky $7 D018796
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x patologie $x terapie $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    12
$a záchranná terapie $7 D016879
650    _2
$a míra přežití $7 D015996
650    _2
$a autologní transplantace $7 D014182
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Santoro, Armando $u Humanitas Cancer Center, Humanitas University, Rozzano-Milan, Italy.
700    1_
$a Shipp, Margaret $u Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Zinzani, Pier Luigi, $d 1959- $u Institute of Hematology "Le A Seràgnoli", University of Bologna, Bologna, Italy. $7 xx0314852
700    1_
$a Timmerman, John M $u University of California, Los Angeles, Los Angeles, CA, USA.
700    1_
$a Ansell, Stephen M. $7 xx0246294 $u Mayo Clinic, Rochester, MN, USA.
700    1_
$a Armand, Philippe $u Dana-Farber Cancer Institute, Boston, MA, USA. $7 gn_A_00008572
700    1_
$a Fanale, Michelle $u University of Texas MD Anderson Cancer Center, Houston, TX, USA.
700    1_
$a Ratanatharathorn, Voravit $u Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
700    1_
$a Kuruvilla, John $u University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada.
700    1_
$a Cohen, Jonathon B $u Winship Cancer Institute, Emory University, Atlanta, GA, USA.
700    1_
$a Collins, Graham $u Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.
700    1_
$a Savage, Kerry J $u Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
700    1_
$a Trněný, Marek, $d 1960- $u Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. $7 nlk20000083659
700    1_
$a Kato, Kazunobu $u Bristol-Myers Squibb, Princeton, NJ, USA.
700    1_
$a Farsaci, Benedetto $u Bristol-Myers Squibb, Princeton, NJ, USA.
700    1_
$a Parker, Susan M $u Bristol-Myers Squibb, Princeton, NJ, USA.
700    1_
$a Rodig, Scott $u Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Roemer, Margaretha G M $u Dana-Farber Cancer Institute, Boston, MA, USA.
700    1_
$a Ligon, Azra H $u Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Engert, Andreas $u University Hospital of Cologne, Cologne, Germany.
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 17, č. 9 (2016), s. 1283-94
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27451390 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20240313113556 $b ABA008
999    __
$a ok $b bmc $g 1239516 $s 984748
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 17 $c 9 $d 1283-94 $e 20160720 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace